PCL is a leading brand in the field of in vitro diagnostic medical devices, specializing in multiplex immunodiagnosis. With their original technology, PCL has successfully commercialized high-risk viral blood screening multiplex immunodiagnostic products, becoming a pioneering company in the industry. They have also developed advanced in vitro diagnostic medical equipment, establishing themselves as leaders in the single immunodiagnostic market.

PCL offers a range of products and services, including mass blood screening multiplex IVD products and a POCT Covid-19 total solution platform. Their innovative platform is based on multiple immune technologies, allowing for the diagnosis of various diseases and providing comprehensive solutions. Led by CEO Soyoun Kim, PCL's mission is to make the fruits of medical innovation accessible to people globally, regardless of their income or background.

Their original technology has garnered international recognition, with patents registered and applied for, as well as collaborations with research institutions worldwide. PCL's headquarters are located in Seoul, South Korea, with a dedicated R&D center. They are committed to advancing in-vitro diagnostics and making a positive impact in the field of immuno-diagnostics